Description
GNF-5 is an inhibitor of Abl that decreases cytokinesis in vitro and displays anti-diabetic, anti-inflammatory, and anti-asthma activities. In vivo, GNF-5 prevents streptozocin-induced loss of pancreatic β-cells and normalizes blood glucose levels. GNF-5 also inhibits OVA-induced increases in IL-13 and CCL2 levels as well as airway resistance in vivo.